1.  Christian Martin Kurbacher, Olympia Horn, Jutta A. Kurbacher, Susanne Herz, Ann T. Kurbacher, Ralf Hildenbrand, Reinhardt Bollmann. Outpatient intraperitoneal Catumaxomab       therapy for malignant ascites related to advanced gynecologic neoplasms. The Ocologist 2015; 20:1333-1341.​​

2.  Schuster FR, Stanglmaier M, Woessmann W, Winkler B, Siepermann M, Meisel R, Schlegel PG, Hess J, Lindhofer H, Borkhardt A, Buhmann R (2014). Immunotherapy with the         trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies. Br J Haematology. 

3.  Pietzner K, Vergote I, Santoro A, Chekerov R, Marme´ F, Rosenberg P, Martinius H, Friccius-Quecke H, Sehouli J (2014). Re-challenge with catumaxomab in patients with                 malignant ascites: results from the SECIMAS study. Med Oncol. 31:308. 

4.  Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R (2012). Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. 

5.  Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D (2012). Humoral response to catumaxomab correlates with clinical               outcome: results of the pivotal phase II/III study in patients with.

6.  Ströhlein M, Lordick F, Rüttinger D, Grützner K, Schemanski O, Jäger M, Lindhofer H, Hennig M, Jauch K, Peschel C, Heiss M (2011). Immunotherapy of Peritoneal 

     Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multi-center, Phase I/II Trial. Onkologie. 34:101-108.

7.  Markus M. Heiss et al., The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III 

     trial. Int. J. Cancer 2010: 127, 2209-2221.

8.  Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H (2008). Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates 

     efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. 123(5):1181-9.

9.  Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M (2006). Phase I trial of the trifunctional anti-HER2 x 

     anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 12(10):3085-91.